FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310946921> ?p ?o ?g. }

• W4310946921 endingPage "211" @default.
• W4310946921 startingPage "203" @default.
• W4310946921 abstract "Only old evidence exists to back up the use of medroxyprogesterone acetate. Therefore, this study aimed to explore the factors that influence the time to treatment failure of medroxyprogesterone acetate in real-world settings as late-line treatment.This was a cohort study that used the database of the Safari study on oestrogen receptor-positive post-menopausal advanced breast cancer (UMIN000015168). We created Kaplan-Meier curves for time to treatment failure with medroxyprogesterone acetate. Further, univariate and multivariate analyses were performed using a Cox hazard model of the clinicopathological factors involved in the time to treatment failure of medroxyprogesterone acetate.From the 1031 patients in the Safari study, 279 patients were selected as the population for the analysis of effectiveness of medroxyprogesterone acetate monotherapy. In the analysis of medroxyprogesterone acetate by treatment line, the median time to treatment failure was 3.0 months for third-line treatment and 4.1 months for fourth and subsequent treatment lines. In cases where medroxyprogesterone acetate was used as a third-line or later endocrine treatment, multivariate analysis showed that the length of the disease-free interval was correlated with the length of time to treatment failure of medroxyprogesterone acetate (P = 0.004). With medroxyprogesterone acetate monotherapy as the fourth-line or later treatment, 20% of the patients achieved a time to treatment failure of 12 months or longer.In actual clinical practice, patients treated with medroxyprogesterone acetate alone as the fourth or subsequent treatment lines showed a time to treatment failure of 4 months, suggesting that there is merit in using medroxyprogesterone acetate even in late treatment lines, especially in patients with long disease-free interval and those who are difficult to treat using other antineoplastic agents." @default.
• W4310946921 created "2022-12-21" @default.
• W4310946921 creator A5011644667 @default.
• W4310946921 creator A5024725726 @default.
• W4310946921 creator A5036168618 @default.
• W4310946921 creator A5036465305 @default.
• W4310946921 creator A5038422646 @default.
• W4310946921 creator A5038871110 @default.
• W4310946921 creator A5040335978 @default.
• W4310946921 creator A5041726660 @default.
• W4310946921 creator A5051908149 @default.
• W4310946921 creator A5052559505 @default.
• W4310946921 creator A5052684223 @default.
• W4310946921 creator A5056628460 @default.
• W4310946921 creator A5060702089 @default.
• W4310946921 creator A5067189124 @default.
• W4310946921 creator A5073950448 @default.
• W4310946921 creator A5081166185 @default.
• W4310946921 creator A5081294000 @default.
• W4310946921 creator A5084823182 @default.
• W4310946921 creator A5085550715 @default.
• W4310946921 creator A5091245889 @default.
• W4310946921 creator A5091623593 @default.
• W4310946921 date "2022-12-08" @default.
• W4310946921 modified "2023-10-07" @default.
• W4310946921 title "Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study" @default.
• W4310946921 cites W1484394791 @default.
• W4310946921 cites W1776991082 @default.
• W4310946921 cites W1943320567 @default.
• W4310946921 cites W1971344086 @default.
• W4310946921 cites W1974769159 @default.
• W4310946921 cites W1978054190 @default.
• W4310946921 cites W2017643572 @default.
• W4310946921 cites W2052450826 @default.
• W4310946921 cites W2052481166 @default.
• W4310946921 cites W2067690477 @default.
• W4310946921 cites W2079704476 @default.
• W4310946921 cites W2085139253 @default.
• W4310946921 cites W2093111077 @default.
• W4310946921 cites W2155803397 @default.
• W4310946921 cites W2255534870 @default.
• W4310946921 cites W2278216532 @default.
• W4310946921 cites W2312296163 @default.
• W4310946921 cites W2314318352 @default.
• W4310946921 cites W2404884142 @default.
• W4310946921 cites W2602089919 @default.
• W4310946921 cites W2766698965 @default.
• W4310946921 cites W2891700678 @default.
• W4310946921 cites W2991938634 @default.
• W4310946921 cites W4210853421 @default.
• W4310946921 cites W4243116045 @default.
• W4310946921 doi "https://doi.org/10.1093/jjco/hyac184" @default.
• W4310946921 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36484305" @default.
• W4310946921 hasPublicationYear "2022" @default.
• W4310946921 type Work @default.
• W4310946921 citedByCount "0" @default.
• W4310946921 crossrefType "journal-article" @default.
• W4310946921 hasAuthorship W4310946921A5011644667 @default.
• W4310946921 hasAuthorship W4310946921A5024725726 @default.
• W4310946921 hasAuthorship W4310946921A5036168618 @default.
• W4310946921 hasAuthorship W4310946921A5036465305 @default.
• W4310946921 hasAuthorship W4310946921A5038422646 @default.
• W4310946921 hasAuthorship W4310946921A5038871110 @default.
• W4310946921 hasAuthorship W4310946921A5040335978 @default.
• W4310946921 hasAuthorship W4310946921A5041726660 @default.
• W4310946921 hasAuthorship W4310946921A5051908149 @default.
• W4310946921 hasAuthorship W4310946921A5052559505 @default.
• W4310946921 hasAuthorship W4310946921A5052684223 @default.
• W4310946921 hasAuthorship W4310946921A5056628460 @default.
• W4310946921 hasAuthorship W4310946921A5060702089 @default.
• W4310946921 hasAuthorship W4310946921A5067189124 @default.
• W4310946921 hasAuthorship W4310946921A5073950448 @default.
• W4310946921 hasAuthorship W4310946921A5081166185 @default.
• W4310946921 hasAuthorship W4310946921A5081294000 @default.
• W4310946921 hasAuthorship W4310946921A5084823182 @default.
• W4310946921 hasAuthorship W4310946921A5085550715 @default.
• W4310946921 hasAuthorship W4310946921A5091245889 @default.
• W4310946921 hasAuthorship W4310946921A5091623593 @default.
• W4310946921 hasConcept C121608353 @default.
• W4310946921 hasConcept C126322002 @default.
• W4310946921 hasConcept C143998085 @default.
• W4310946921 hasConcept C207103383 @default.
• W4310946921 hasConcept C2775934596 @default.
• W4310946921 hasConcept C2776306185 @default.
• W4310946921 hasConcept C2777164284 @default.
• W4310946921 hasConcept C2908647359 @default.
• W4310946921 hasConcept C29456083 @default.
• W4310946921 hasConcept C44249647 @default.
• W4310946921 hasConcept C50382708 @default.
• W4310946921 hasConcept C530470458 @default.
• W4310946921 hasConcept C71924100 @default.
• W4310946921 hasConcept C99454951 @default.
• W4310946921 hasConceptScore W4310946921C121608353 @default.
• W4310946921 hasConceptScore W4310946921C126322002 @default.
• W4310946921 hasConceptScore W4310946921C143998085 @default.
• W4310946921 hasConceptScore W4310946921C207103383 @default.
• W4310946921 hasConceptScore W4310946921C2775934596 @default.
• W4310946921 hasConceptScore W4310946921C2776306185 @default.

• next